At Investor Conferences

 
 

Business Parks & Science Centres

 
 
 

Advertisement

Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 600x94px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in France and Monaco or involving organisations from these countries.

Total search results: 1708 | Ordered by Date (descending)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Theranexus–IRISA (FR): bioinformatics, 210904– collab using AI for targeting neuroglial interactions for drug discovery with Dyliss Group 2019-04-09
AgomAb Therapeutics–Advent France Biotechnology: investment, 201904 financing round Series A totalling €21m incl co-lead investor Advent France 2019-04-03
AgomAb Therapeutics–Boehringer: investment, 201904 financing round Series A totalling €21m incl co-investor BIVF 2019-04-03
AgomAb Therapeutics–Omnes Capital: investment, 201904 financing round Series A totalling €21m incl co-investor Omnes 2019-04-03
AgomAb Therapeutics–Pontifax: investment, 201904 financing round Series A totalling €21m incl co-investor Pontifax 2019-04-03
AgomAb Therapeutics–SEVERAL: investment, 201904 financing round Series A €21m co-led by V-Bio Ventures + Advent France Biotechnology 2019-04-03
AgomAb Therapeutics–V-Bio Ventures: investment, 201904 financing round Series A totalling €21m incl co-lead investor V-Bio Ventures 2019-04-03
Karuna–Sofinnova: investment, 201903–201904 financing round Series B totalling $80m incl $12m from new investor Sofinnova Investments 2019-04-01
Cellnovo–NONE: investment, 201903 in administration 2019-03-28
Polyneuron–New Enterprise Associates: investment, 201903 financing round Series A totalling CHF22.5m incl new + co-lead investor NEA 2019-03-28
Polyneuron–SEVERAL: investment, 201903 financing round Series A CHF22.5m led by Sofinnova Partners + incl NEA 2019-03-28
Polyneuron–Sofinnova: investment, 201903 financing round Series A totalling CHF22.5m incl new + lead investor Sofinnova Partners 2019-03-28
H4Orphan Pharma–Cerenis: investment, 201903–201904 excl merger negotations w Cerenis owning 59% of combined company TERMINATED 4/19 2019-03-27
Pierre Fabre–Institut Curie: cancer immunotherapy, 201903– collab extension I-O drug target discovery with IRPF 2019-03-21
Pfizer–Vivet Therapeutics: VTX-801, collab developm €45m (incl acqu 15% share) + €560m milestones (incl acquisition of Vivet) 2019-03-20
Vivet Therapeutics–Pfizer: investment, 201903 acquisition 15% equity interest plus excl option to acquire all outstanding shares 2019-03-20
BPCE–SEVERAL: investment, 201903 first closing €na of Seventure Health for Life Capital II Fund with final target size of over €200m 2019-03-05
Novasep–Sartorius: chromatography, 201903– collab developm of systems for membrane chromatography SSB 2019-03-05
Anaeropharma Science–BPCE: investment, 201903 existent portfolio company of Seventure Partners 2019-03-01
Humedics–BPCE: investment, 201903 existent portfolio company of Seventure Partners 2019-03-01
MycoTechnology–BPCE: investment, 201903 existent portfolio company of Seventure Partners 2019-03-01
TargEDys–BPCE: investment, 201903 existent portfolio company of Seventure Partners 2019-03-01
Genfit–SEVERAL: investment, 201902–201903 private placement €9m with 500k ordinary shares at €18/share in Europe + outside North America 2019-02-27
Genfit–SEVERAL: investment, 201902–201903 US IPO $125m with 6.15m ADSs at $20.32/ADS at Nasdaq Global Select Market 2019-02-27
Ynsect–SEVERAL: investment, 201902 financing round Series C €110m ($1245m) led by Astanor Ventures 2019-02-21
BiomX–BPCE: investment, 201902 financing round Series B totalling $32m incl existing + co-lead investor Seventure Health for Life Capital fund 2019-02-20
BiomX–SEVERAL: investment, 201902 financing round Series B $32m led by existing investors OrbiMed + JJDC + Takeda Ventures et al 2019-02-20
BPCE–Yucatan: public relations, 201902 service existent media relations for Seventure Parnters in France by Agence Yucatan 2019-02-20
Arvelle Therapeutics–SEVERAL: investment, 201902 financing round Series A $180m with global investor syndicate 2019-02-14
Arvelle Therapeutics–SK Group: cenobamate, 201902– license excl for Europe $110m upfront + $430m milestones + royalties from SK Biopharmaceuticals 2019-02-14
CiToxLab–Charles River: investment, 201902– acquisition $448m in cash BINDING OFFER SIGNED 2019-02-13
Grey Wolf Therapeutics–Andera Partners: investment, 201902 financing round Series A totalling £10m with Andera Partners + Canaan 2019-02-11
Grey Wolf Therapeutics–Canaan Partners: investment, 201902 financing round Series A totalling £10m with Andera Partners + Canaan 2019-02-11
Grey Wolf Therapeutics–SEVERAL: investment, 201902 financing round Series A £10m with Andera Partners + Canaan 2019-02-11
Invisible Sentinel–Mérieux: investment, 201902 acquisition $75m in cash by bioMérieux 2019-02-07
Axial Biotherapeutics–BPCE: investment, 201902 financing round Series B totalling $25m incl new investor Seventure Partners 2019-02-01
Axial Biotherapeutics–SEVERAL: investment, 201902 financing round Series B $25m incl Seventure Partners 2019-02-01
Pharnext–CB Lux: investment, 201901 private placement €15m with 1.02m new shares at €14.7/share to CB Lux raising share from 21.12% to 27.79% 2019-01-23
ImaBiotech–Metabrain Research: preclinical research services, 201901– collab strategic partnership ADMET services in preclin metabolic disease models 2019-01-17
ImaBiotech–OCR (FR): preclinical research services, 201901– collab strategic partnership oncology research in pet tumors using bioanalytical imaging 2019-01-17
Nanobiotix–RooneyPartners: public relations, 201901 service existent US media relations by RooneyPartners 2019-01-16
Nanobiotix–SEVERAL: investment, 201901– filing of Form F-1 for registered public offering of shares + ADSs in US conditions to be determined later 2019-01-16
Sanofi–Biomunex: antibody technology, 201901– license €na to use BiXAb technology to generate + develop bi- + multi-specific antibodies 2019-01-15
Sophia Genetics–Alychlo: investment, 201901 financing round totalling $77m incl existing + co-investor Alychlo 2019-01-04
Sophia Genetics–Balderton Capital: investment, 201901 financing round totalling $77m incl existing + co-investor Balderton Capital 2019-01-04
Sophia Genetics–Generation Investment Management: investment, 201901 financing round totalling $77m incl new + lead investor Generation 2019-01-04
Sophia Genetics–Idinvest Partners: investment, 201901 financing round totalling $77m incl new + co-investor Idinvest Partners 2019-01-04
Sophia Genetics–SEVERAL: investment, 201901 financing round $77m incl new + lead investor Generation Investment Management LLP 2019-01-04
MycoTechnology–SEVERAL: investment, 201901 financing round Series C $30m 2019-01-01
Vedanta Biosciences–BMS: investment, 201812 financing round Series C totalling $27m incl new investor BMS 2018-12-24
Vedanta Biosciences–BPCE: investment, 201812 financing round Series C totalling $27m incl existing investor Seventure Partners 2018-12-24
Vedanta Biosciences–Gates Foundation: investment, 201812 financing round Series C totalling $27m incl new investor Gates Foundation 2018-12-24
Vedanta Biosciences–Invesco: investment, 201812 financing round Series C totalling $27m incl existing investor Invesco Asset Management 2018-12-24
Vedanta Biosciences–PureTech Health: investment, 201812 financing round Series C totalling $27m incl existing investor PureTech Health 2018-12-24
Vedanta Biosciences–Rock Springs Capital: investment, 201812 financing round Series C totalling $27m incl existing investor Rock Springs Capital 2018-12-24
Vedanta Biosciences–SEVERAL: investment, 201812 financing round Series C $27m Gates + BMS + Rock Springs Capital + Invesco + Seventure + PureTech 2018-12-24
France (govt)–Novartis: investment, 201812– proposed acquisition of CellforCure from LFB by Novartis 2018-12-20
Carmat–EU (govt): credit, 201812– EFSI €30m loan from EIB to move artificial heart towards marketing 2018-12-17
Kurma–France (govt): investment, 201812 first closing of Kurma Biofund III incl cornerstone investors Servier + Bpifrance + Idinvest 2018-12-14
Kurma–Idinvest Partners: investment, 201812 first closing of Kurma Biofund III incl cornerstone investors Servier + Bpifrance + Idinvest 2018-12-14
Kurma–NewCap: public relations, 201812 service existent by NewCap 2018-12-14
Kurma–Servier: investment, 201812 first closing of Kurma Biofund III incl cornerstone investors Servier + Bpifrance + Idinvest 2018-12-14
Kurma–SEVERAL: investment, 201812 first closing of Kurma Biofund III with target for final closing of €150m 2018-12-14
Pharvaris–Kurma: investment, 201812 existing founding investor Kurma Biofund II 2018-12-14
Step Pharma–Kurma: investment, 201812 existing founding investor Kurma Biofund II 2018-12-14
genOway–Merck (DE): CRISPR technology, 201812– collab strategic alliance €na incl ww excl license to produce + sell genome-edited rodent models 2018-12-10
Hookipa–Valneva: drug development services, 201812–202111 collab + manufacturing agreem for developm of immunotherapies with Valneva Sweden AB 2018-12-06
Sillages Paris–L’Oréal: investment, 201812 acquisition of minority share by BOLD fund as inaugural investment of BOLD 2018-12-05
Anagenesis–Alsace (govt): investment, 201812 financing round Series A 1st closing totalling €3m incl existing investor Cap Innov’Est 2018-12-04
Anagenesis–Boehringer: investment, 201812 financing round Series A 1st closing totalling €3m incl new investor BIVF 2018-12-04
Anagenesis–SEVERAL: investment, 201812 financing round Series A €3m 1st closing from BIVF + Cap Innov’Est 2018-12-04
Boehringer–Domain Therapeutics: drug discovery services, 201812– collab + license agreem €na discovery of GPCR-targeting CNS drugs 2018-12-04
Celyad–Bryan Garnier: investor conference, 201811 supply service Celyad participates at Bryan Garnier Annual Healthcare Conference in Paris 2018-11-22
Erytech–Infopro Digital: investor conference, 201811 supply service Erytech at Actionaria 2018 in Paris 2018-11-22
Stilla Technologies–Alize RP: public relations, 201811 service existent PR EU by Alize RP 2018-11-20
Stilla Technologies–BNP Paribas: investment, 201811 financing round Series A totalling €16m incl co-investor BNP Paribas Développement 2018-11-20
Stilla Technologies–Idinvest Partners: investment, 201811 financing round Series A totalling €16m incl co-investor Idinvest Partners 2018-11-20
Stilla Technologies–Illumina: investment, 201811 financing round Series A totalling €16m incl lead investor Illumina Ventures 2018-11-20
Stilla Technologies–Kurma: investment, 201811 financing round Series A totalling €16m incl co-investor Kurma Partners 2018-11-20
Stilla Technologies–LBO France: investment, 201811 financing round Series A totalling €16m incl co-investor LBO France 2018-11-20
Stilla Technologies–Paris Saclay Seeds: investment, 201811 financing round Series A totalling €16m incl co-investor Paris Saclay Seeds 2018-11-20
Stilla Technologies–SEVERAL: investment, 201811 financing round Series A €16m led by Illumina Ventures 2018-11-20
Erytech–Leucadia: investor conference, 201811 supply service Erytech at Jefferies London Healthcare Conference 2018 2018-11-14
IntegraGen–Alphabet: bioinformatics, 201811 collab implementation of Sirius + Mercury genomic analsys tools in Google Cloud 2018-11-12
Q-Bioanalytic–Eurofins: investment, 201811 acquisition by Eurofins 2018-11-01
Sanofi–Denali Therapeutics: RIPK1 inhibitors, 201811– collab $125m upfront + >$1b + royalties RIPK1 inhibitors incl DNL 747 + DNL 758 2018-11-01
Magnisense–SEVERAL: investment, 201810 financing round €5m from new + existing investors incl Meusinvest + Provestis + Concorde Capital + Minv 2018-10-24
Microbiotica–BPCE: investment, 201810 investment £4m by Seventure Partners’ Health for Life Capital Fund 2018-10-24
Enterome–Rx Communications: public relations, 201810 service existent IR by Rx Communications Group 2018-10-23
Acticor Biotech–CapDecisif: investment, 201810 financing round Series B totalling €15.3m incl existing + co-investor CapDecisif Management (HK) 2018-10-17
Acticor Biotech–China Medical System: investment, 201810 financing round Series B totalling €15.3m incl new + co-investor CMS Medical Venture 2018-10-17
Acticor Biotech–Mirae Asset: investment, 201810 financing round Series B totalling €15.3m incl new + co-investor Mirae Asset Capital Co Ltd 2018-10-17
Acticor Biotech–NewCap: public relations, 201810 service existent by NewCap 2018-10-17
Acticor Biotech–Newton Biocapital: investment, 201810 financing round Series B totalling €15.3m incl new + lead investor Newton Biocapital 2018-10-17
Acticor Biotech–PERSON: investment, 201810 financing round Series B totalling €15.3m incl new + co-investor A&B (HK) 2018-10-17
Acticor Biotech–SEVERAL: investment, 201810 financing round Series B €15.3m led by new investor Newton Biocapital 2018-10-17
Erytech–EZIL: investor conference, 201810 supply service Erytech at European Large & Midcap Event in Paris 2018-10-09
Rgenix–SEVERAL: investment, 201810 financing round Series C $40m led by Lepu Medical + incl Novo Holdings + Sofinnova Partners et al 2018-10-09
Sitryx Therapeutics–GSK: investment, 201810 financing round Series A totalling $30m incl co-investor GSK 2018-10-08
Sitryx Therapeutics–Longwood Fund: investment, 201810 financing round Series A totalling $30m incl co-investor Longwood Fund 2018-10-08
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18  next pagenext page



Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

» top